This systematic review examined the safety of hormone replacement therapy (HRT) in BRCA1 and BRCA2 mutation carriers who have undergone risk-reducing salpingo-oophorectomy (RRSO). The findings indicate that short-term HRT does not increase breast cancer risk or reduce the protective effects of RRSO in women without a personal history of breast
